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TheAMP-activated protein kinase (AMPK) is a sensor of cellular energy and nutrient status, expressed almost
universally in eukaryotes as heterotrimeric complexes comprising catalytic (a) and regulatory (b and g) sub-
units. Along with themechanistic target of rapamycin complex-1 (mTORC1), AMPKmay have been one of the
earliest signaling pathways to have arisen during eukaryotic evolution. Recent crystal structures have pro-
vided insights into themechanisms bywhich AMPK is regulated by phosphorylation and allosteric activators.
Another recent development has been the realization that activation of AMPK by the upstream kinase LKB1
may primarily occur not in the cytoplasm, but at the surface of the lysosome, where AMPK and mTORC1 are
regulated in a reciprocal manner by the availability of nutrients. It is also becoming clear that there is a sub-
stantial amount of crosstalk between the AMPK pathway and other signaling pathways that promote cell
growth and proliferation, and this will be discussed.The AMP-activated protein kinase (AMPK) is a ubiquitous
sensor of cellular energy and nutrient status in eukaryotic cells.
Because of the adenylate kinase reaction (2ADP4 ATP +AMP),
which appears to be maintained close to equilibrium in essen-
tially all cells, increases in the cellular ADP:ATP ratio (signaling
a deficit in cellular energy) are always accompanied by even
larger increases in the AMP:ATP ratio (Gowans et al., 2013).
AMPK monitors the ratio of AMP:ATP (and, to a lesser extent,
ADP:ATP) and, if energy deficit is detected, acts to restore
energy homeostasis by switching on alternate catabolic path-
ways that produce ATP while switching off biosynthetic path-
ways and other nonessential processes consuming ATP. The
pathway appears to have arisen very early during eukaryotic
evolution because AMPK orthologs are found in essentially all
eukaryotes, including protists, fungi, plants, and animals. One
interesting exception that ‘‘proves the rule’’ is the microspori-
dian parasite Encephalitozoon cuniculi, a eukaryote that lives
as an obligate parasite within mammalian cells. It has an
extremely small genome encoding only 29 conventional protein
kinases, which lacks any genes encoding AMPK subunits
(Miranda-Saavedra et al., 2007). Its genome does encode a
glycolytic pathway, but it lacks functional mitochondria and
appears to ‘‘steal’’ ATP from its host cell by means of ATP:ADP
translocases located in its plasma membrane (Tsaousis et al.,
2008). Rather than being an ancestral eukaryote that never con-
tained AMPK, it therefore seems more likely that E. cuniculi,
which has been able to strip its genome down to the bare
minimum due to its existence as an obligate parasite, has
dispensed with AMPK because its host cell contains AMPK
and can maintain energy homeostasis on its behalf.
A major event within the last year was the publication of the
first complete crystal structure for a human AMPK complex
(Xiao et al., 2013), and I discuss below how this and related struc-
tural studies have illuminated the mechanism by which the
AMPK system senses cellular energy. While AMPK was viewed
at one time as a system that operated rather independently of
other signaling pathways, as the field matured it was perhapsinevitable that an increasing amount of crosstalk with pathways
regulating cell growth and proliferation would be found. The past
year or so has also seen major developments in this area, partic-
ularly in the interaction with the mechanistic target of rapamycin
complex-1 (mTORC1) pathway. This will form another major
theme of this review. Readers interested in other aspects of
AMPK function, such as the identification of downstream tar-
gets, its anticancer or anti-inflammatory effects, or its role in
the regulation of whole-body energy balance, should consult
other recent reviews (Hardie, 2014; Hardie and Ashford, 2014;
Hardie et al., 2012; O’Neill and Hardie, 2013; Steinberg et al.,
2013).
Canonical Regulation by Phosphorylation and by
Adenine Nucleotides
AMPK appears to exist in all eukaryotes as heterotrimeric com-
plexes comprising catalytic a subunits and regulatory b and g
subunits. In mammals, these occur as multiple subunit isoforms
(a1/a2, b1/b2, g1/g2/g3) encoded by distinct genes, which can
form at least 12 distinct heterotrimeric combinations. The ki-
nase activity of the a subunit increases >100-fold following
phosphorylation at a conserved threonine residue within the
activation loop of the kinase domain (usually called Thr172
due to its position in rat a1/a2; Hawley et al., 1996). The major
upstream kinase phosphorylating this site was identified as a
heterotrimeric complex containing the tumor suppressor kinase
LKB1, the pseudokinase STRAD, and the scaffold protein
MO25 (Hawley et al., 2003; Shaw et al., 2004; Woods et al.,
2003). Subsequently, an alternate upstream pathway was
discovered in which Thr172 is phosphorylated by calmodulin-
dependent kinase kinases (CaMKKs), especially CaMKKb
(Hawley et al., 2005; Hurley et al., 2005; Woods et al., 2005).
The Ca2+-dependent and AMP-dependent pathways occur
independently, although because AMP acts in part by inhibiting
Thr172 dephosphorylation (see below) the two can act syner-
gistically if both Ca2+ and AMP are elevated (Fogarty et al.,
2010).Cell Metabolism 20, December 2, 2014 ª2014 Elsevier Inc. 939
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Figure 1. Structures of a Selection of Three Different Classes of
AMPK-Activating Compounds
(A) Mitochondrial inhibitors that increase cellular AMP/ADP.
(B) Prodrugs converted to AMP analogs within cells.
(C) Direct activators of AMPK.
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activity of at least 12 AMP-related kinases, which have kinase
domains related to AMPK but do not have the other domains
or subunits associated with it (Lizcano et al., 2004). The activities
of LKB1 or these AMPK-related kinases do not appear to change
under conditions of metabolic stress where AMPK is activated in
an LKB1-dependent manner, such as during muscle contraction
(Sakamoto et al., 2004, 2005). This implies that regulation of
AMPK under these circumstances is primarily due to signals
acting on the downstream kinase (AMPK) rather than on the
upstream kinase (LKB1). As in other situations of metabolic
stress, muscle contraction is accompanied by increases in the
AMP:ATP and ADP:ATP ratios (Sakamoto et al., 2005), and
numerous studies in cell-free systems have revealed that binding
of AMP and/or ADP to AMPK activates the kinase by three com-
plementary mechanisms, all of which are antagonized by binding
of ATP:940 Cell Metabolism 20, December 2, 2014 ª2014 Elsevier Inc.(1) AMP binding promotes Th172 phosphorylation by the
LKB1 complex. It has been suggested that binding of
ADP also promotes phosphorylation by CaMKKb (Oakhill
et al., 2010, 2011), but the author’s group found, using
both nucleotides at 300 mM, that this effect was specific
for AMP and only operated with LKB1 and not CaMKKb
(Gowans et al., 2013). Major new insights into the mecha-
nism by which LKB1 activates AMPK in intact cells have
been obtained within the last year and will be discussed
later.
(2) AMP binding causes a conformational change that in-
hibits dephosphorylation of Thr172 by protein phospha-
tases (Davies et al., 1995). It was subsequently reported
that binding of ADP, as well as AMP, can produce this
effect (Xiao et al., 2011). The author’s group finds that
the effect of ADP requires concentrations about 10-fold
higher than those of AMP, although this is compensated
by the fact that cellular concentrations of ADP are usually
also about 10-fold higher than AMP. Both nucleotides
may therefore contribute to the effect in intact cells,
although we have argued that AMP may be the more
important physiological activator because the changes
in AMP in cells undergoing stress are always much larger
than those in ADP (Gowans et al., 2013).
(3) Binding of AMP, but not ADP, causes allosteric activation
of the kinase. Under appropriate conditions, the degree of
allosteric activation by AMP can be substantial (>10-fold),
even in the presence of physiological ATP concentrations
(5 mM) (Gowans et al., 2013).Activation by Natural Products and Synthetic Activators
Given the great potential of AMPK activators as therapeutic
agents (Hardie, 2013), many high-throughput screens have
been conducted and numerous activators found; the structures
of some of these are shown in Figure 1. They can be divided into
three major classes according to their mechanism of action:
(1) Indirect activators that inhibit cellular ATP production and
thus increase cellular AMP:ATP and ADP:ATP ratios
(Figure 1A): most of these compounds reduce ATP pro-
duction by inhibiting the respiratory chain, although
resveratrol, quercetin, and oligomycin inhibit the mito-
chondrial ATP synthase (F1F0-ATPase) (Gledhill et al.,
2007), while 2-deoxyglucose inhibits glycolysis. This
mechanism is most clearly demonstrated using cells ex-
pressing a mutation in the AMPK-g subunit (e.g., R531G
in g2) that prevents binding of AMP at the critical acti-
vating site; this class of compound fails to activate the
mutant kinase. This approach has been used to show
that the antidiabetic drug metformin, the glycolytic inhib-
itor 2-deoxyglucose, and the plant products, resveratrol,
berberine, and galegine (metformin was derived from
the latter), all act via this mechanism (Hawley et al.,
2010). In the last 2 or 3 years, a bewildering variety of
natural plant products, many of which (like berberine)
have been used in traditional Asian medicine, has been
shown to activate AMPK. The author recently compiled
a list of over 50 such compounds (Hardie, 2014). While
their mechanism of action has not been established in
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mitochondrial poisons produced by plants as a defensive
mechanism. Following the aphorism of Paracelsus that
‘‘the dose makes the poison,’’ at high doses these com-
poundsmay act asmitochondrial poisons that deter graz-
ing of the plant by animals or insects, or infection by plant
pathogens, while at lower doses they may have useful
therapeutic properties by causing a mild inhibition of
ATP synthesis that activates AMPK.
(2) Compounds that are prodrugs converted into AMP
analogs inside cells: the founding member of this
class is 5-aminoimidazole-4-carboxamide ribonucleoside
(AICAR), a nucleoside that is taken up into cells by aden-
osine transporters (Gadalla et al., 2004) and then phos-
phorylated to the equivalent nucleotide ZMP (Figure 1B).
ZMP is an AMP analog that mimics all three effects of
AMP on the AMPK system (Corton et al., 1995) and binds
to the same site(s) as AMP, so the effects of AICAR are
also abolished by the R531G mutation (Hawley et al.,
2010). For many years, AICAR was the only member
of this class, but recently a new AMP analog, 5-(5-
hydroxyl-isoxazol-3-yl)-furan-2-phosphonic acid or C2,
was reported to be 100-fold more potent than AMP and
over 1,000-fold more potent than ZMP as an AMPK acti-
vator in cell-free assays. Since it carries a negatively
charged phosphonate group, C2 is not cell permeable,
but it can be administered to cells in the form of the pro-
drug C13 (Figure 1B) in which the phosphonate group is
esterified; C13 is converted into C2 by intracellular ester-
ases. Unlike ZMP, C2 has the advantage that it does not
affect other AMP-sensitive metabolic enzymes, such as
glycogen phosphorylase or fructose-1,6-bisphosphatase
(Go´mez-Galeno et al., 2010). Like AMP and ZMP, C2
causes both allosteric activation and protection against
Thr172 dephosphorylation, and its effects are abolished
by the R531G mutation; but unlike AMP and ZMP, it is a
selective activator of complexes containing AMPK-a1
rather than AMPK-a2 (Hunter et al., 2014).
(3) Direct AMPK activators whose binding involves the b sub-
unit carbohydrate-binding module: the recently recog-
nized binding site for this class of AMPK activator is
described in more detail in the section on AMPK structure
below. The first activator in this class was the thienopyri-
done A769662 (Cool et al., 2006), which directly activates
AMPK, mimicking the effects of AMP to cause allosteric
activation and protect against Thr172 dephosphorylation
(Go¨ransson et al., 2007; Sanders et al., 2007). A769662
acts in an AMP-independent manner, since it activates
AMPK in cells expressing the AMP-insensitive R531G
mutant (Hawley et al., 2010). Even before the exact bind-
ing site had been clarified, it was clear that it involved the b
subunit, because activation was more effective with b1
than b2 complexes (Scott et al., 2008) and was abolished
by a mutation within b1 (S108A) that prevents autophos-
phorylation of that serine residue (Sanders et al., 2007).
Recently, two new activators, 991 and MT-63-78, have
been described (Figure 1C). Crystallography showed
that 991 binds in the same site as A769662 (Xiao et al.,
2013), while MT-63-78 also shows selectivity for b1 com-plexes (Zadra et al., 2014) and is therefore likely to bind
the same site. The presence of a well-defined binding
site for these synthetic activators raises the intriguing
question as to whether there are natural ligands that
bind this site. Salicylate (derived originally from the bark
of the white willow, Salix alba) has been used as a medi-
cine for thousands of years and is the natural product
from which aspirin was derived. Aspirin is an acetyl ester
that is rapidly broken down to salicylate following its
adsorption from the gut. Its acetyl group (not present in
salicylate) irreversibly inactivates the cyclo-oxygenases
(COX1 and COX2) that catalyze the key step in prostanoid
biosynthesis, which are generally regarded as the main
targets of aspirin. However, the very short half-life of
aspirin in the circulation (a few minutes) compared with
salicylate (several hours) raises doubts as to whether all
of the therapeutic effects of aspirin are mediated by this
mechanism (Steinberg et al., 2013). Salicylate, but not
aspirin, activates AMPK in intact cells at concentrations
that occur in plasma of humans taking high doses of
aspirin (Hawley et al., 2012). Like A769662 or 991, activa-
tion by salicylate is selective for b1 complexes and is abol-
ished by an S108A mutation in b1, so these compounds
all appear to bind at the same site. In mice, treatment
with either salicylate or A769662 caused a more rapid
switch from carbohydrate to fat oxidation at the onset of
fasting, but these metabolic effects were absent in b1
knockout mice, providing strong evidence that they
were mediated by AMPK activation (Hawley et al.,
2012). While salicylate is a natural ligand, it is a plant prod-
uct, and this leaves open the question as to whether there
are naturally occurring ligands binding at the A769662 site
that are produced by mammals.
Allosteric Activation in the Absence of Thr172
Phosphorylation
Since phosphorylation of AMPK at Thr172 increases its activity
by >100-fold, the dephosphorylated enzyme has generally
been regarded as inactive, and many researchers have used
the degree of Thr172 phosphorylation (assessed using phospho-
specific antibodies) as a surrogate for AMPK activation. How-
ever, recent results suggest that this may not always be valid
(Scott et al., 2014). A769662was found to cause a very large allo-
steric activation of either wild-type AMPK not phosphorylated on
Thr172 or a nonphosphorylatable T172Amutant (65- or 100-fold,
respectively). However, maximal activation required either prior
autophosphorylation of Ser108 or a phosphomimetic mutation
(S108E) at that residue. Remarkably, a T172A/S108E double
mutant was activated z900-fold by A797662, and in the pres-
ence of AMP (which caused 20-fold activation on its own) this
increased to z2,500-fold, reaching a final activity comparable
with that obtained with the maximally phosphorylated wild-
type kinase. Thus, combined allosteric activation by A-769662
and AMP can achieve the same final activity with or without
Thr172 phosphorylation, although this does require Ser108 to
be phosphorylated. In the same study, it was shown that
Ser108 was modified by cis-autophosphorylation and that,
following a pulse of CaMKKb activation in COS7 cells, dephos-
phorylation of Ser108 was slower than that of Thr172. ThisCell Metabolism 20, December 2, 2014 ª2014 Elsevier Inc. 941
Figure 2. Structure of Complete a2b1g1 Heterotrimer of AMPK
The model was created with MacPyMol using PDB file 4CFE. The a, b, and g
subunits are shown in ‘‘cartoon view’’ with different domains color coded,
while the activator 991, the kinase inhibitor staurosporine, the three bound
molecules of AMP, and phospho-Thr172 are shown in ‘‘sphere view’’ with C
atoms green, O red, N blue, and P orange. Various features labeled are dis-
cussed in the text.
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phosphorylation (which would trigger Ser108 autophosphoryla-
tion), the binding of activators at both the A769662 and AMP
sites might then cause a hyperactivated state that could
continue even after Thr172 was dephosphorylated, as long as
Ser108 remained phosphorylated. Another interesting possibility
is that there might be a distinct upstream kinase for Ser108.
While these findings are intriguing, their true physiological signif-
icance may only become clear when a natural ligand that binds
the A769662 site has been identified. However, they do show
that relying on Thr172 phosphorylation alone as a marker for
AMPK activation is inadvisable and that the phosphorylation of
a downstream target such as acetyl-CoA carboxylase should
also be monitored. While unlikely to be relevant to the mecha-
nism described by Scott et al. (2014), others have found situa-
tions in vivo where changes in AMPK activity measured in
immunoprecipitates (and therefore not due to allosteric effects)
did not appear to be associated with changes in Thr172 phos-
phorylation (Dagon et al., 2012; Pulinilkunnil et al., 2011).
AMPK: Structure and Regulation
I will now discuss how the recent crystal structure of a complete
human a2b1g1 complex (Xiao et al., 2013), together with analysis
of previous partial structures, has illuminated the regulatory
mechanisms described above. The structure of the heterotrimer
can be divided into two major sections, i.e., the ‘‘catalytic mod-
ule’’ (Figure 2, bottom left) and the ‘‘nucleotide-binding module’’
(Figure 2, top right). The critical phosphorylation site, Thr172, lies
in the cleft between these two modules, where access to up-
stream kinases and phosphatases may be particularly sensitive
to conformational changes. The structures of the three subunits
within the heterotrimer will now be discussed in turn.942 Cell Metabolism 20, December 2, 2014 ª2014 Elsevier Inc.The a Subunit
The kinase domain at the N terminus of the a subunit has the
small N-lobe and larger C-lobe of a typical serine/threonine ki-
nase domain, with the active site that binds MgATP (which in
this structure contained the kinase inhibitor staurosporine)
located in the cleft between them. Despite this bound inhibitor,
the kinase domain was in an active conformation because
Thr172 had been phosphorylated prior to crystallization and
because the construct was also crystallized in the presence of
two activating ligands, i.e., AMP and 991. In addition, the four
hydrophobic residues that form the regulatory spine (Leu68
and Leu79 from the N-lobe, and His137 and Phe158 from the
C-lobe) were aligned as in other active kinases (Taylor and Kor-
nev, 2011). Within the a subunit sequence, the kinase domain
(KD) is immediately followed by the autoinhibitory domain
(AID), so called because KD-AID constructs are around 10-fold
less active than constructs containing the KD alone, even after
phosphorylation on Thr172 (McBride et al., 2009; Pang et al.,
2007). Structures for a KD-AID construct from the fission yeast
Schizosaccharomyces pombe (Chen et al., 2009), and for two
isolated rat and human AIDs (Chen et al., 2013), show that
AIDs form a compact bundle of three a helices. In the structure
of the S. pombe KD-AID (Chen et al., 2009), where the kinase
is in an inactive conformation with the regulatory spine out of
alignment, helix a3 of the AID interacts with the rear of the kinase
domain (i.e., the opposite side to the active site), forming interac-
tions with residues in the C-helix of the N-lobe and the E-helix of
the C-lobe that appear to maintain the kinase domain in an inac-
tive conformation (Figure 3, left). Although the AID was not fully
resolved in the human structure (Xiao et al., 2013), it was clear
by comparison with the S. pombe KD-AID structure that the
AID had undergone a major rotation, so that helix a3 within it
now interacts with the g subunit, rather than with the N- and
C-lobes of the kinase domain (Figure 3, right). The first part of
the linker between the AID and the C-terminal domain of the a
subunit (the a-linker) forms the hinge between the catalytic
module and the nucleotide-binding module, and the binding of
this linker to the AMP-bound g subunit appears to cause this re-
orientation of the AID. This is discussed in more detail below in
the section describing the g subunit.
The globular C-terminal domain of the a subunit terminates
with an a helix that carries a well-defined nuclear export
sequence. A similar sequence is found in both the a1 and a2 iso-
forms, although it has only been shown to be functional as a
nuclear export sequence in the case of a2 (Kazgan et al.,
2010). Just prior to this a helix, there is a long serine/threonine-
rich loop that has not been resolved in any of the crystal struc-
tures. We refer to this as the ST loop, and its function will be
discussed later.
The b Subunit
Within the b1 subunit, only the two conserved regions found in b
subunits from all species (i.e., the carbohydrate-binding module
[CBM] and the C-terminal domain) were fully resolved in the
structure (Xiao et al., 2013). The CBM is related to noncatalytic
domains found in enzymes that bind starch and glycogen and
has been shown to be responsible for the binding of a proportion
of AMPK to the surface of glycogen particles (Hudson et al.,
2003; McBride and Hardie, 2009; Polekhina et al., 2003, 2005).
The physiological role of glycogen binding is not completely
Figure 3. Comparison of Structure of the
Inactive KD:AID Fragment from S. pombe,
and the Active KD:AID Fragment from
Human a2, Showing the Dramatic Change in
the Position of the AID
The models were created with McPymol using
PDB entries 3H4J and 4CFE (although the latter
was a complete heterotrimer, only the KD and AID
are shown). The kinase domains are viewed from
approximately the same angle, so that the change
in the orientation of the AID is more obvious. The
N- and C-lobes of the kinase domain are in yellow
and cyan, respectively, except that the activation
segments within the C-lobe (which have markedly
different conformations in the two structures) are in
red. The AIDs are in orange, with their three a he-
lices labeled AID-a1 to AID-a3 (AID-a2 was poorly
resolved in the human structure). In the inactive
S. pombe structure, AID-a3 interacts with aC
(C-helix) from the N-lobe and aE (E-helix) from the
C-lobe, whereas in the active human structure it
interacts mainly with the g subunit (not shown)
instead.
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thase, whose phosphorylation by AMPK causes inactivation of
both the muscle and liver isoforms and thus inhibits glycogen
synthesis (Bultot et al., 2012; Carling and Hardie, 1989; Jørgen-
sen et al., 2004). One of the most intriguing features of the new
heterotrimer structure is that the CBM sits next to the N-lobe
of the kinase domain, with the cleft between them providing
the binding site for the synthetic AMPK activators 991 and
A769662 (Figure 2). Ser108 within the CBM, whichmust be auto-
phosphorylated to allow full activation by A769662 and salicy-
late, is not directly involved in binding of these ligands, but
when phosphorylated it forms electrostatic interactions between
the CBM and the N-lobe of the kinase domain that stabilize the
binding cleft. The CBM is followed in the b1 subunit sequence
by the C-interacting helix, which interacts with the C-helix of
the N-lobe of the kinase domain. It seems likely that this interac-
tion transmits the effects of binding of A769662-like activators to
the active site because a change in the position of the N-terminal
end of the C-helix is one of the critical steps that must be
achieved for activation of many kinases (Taylor and Kornev,
2011).
Turning to the C-terminal domain of the b subunit, the first
portion has an extended conformation that interacts with the
C-terminal domain of the a subunit. It then takes an excursion
termed the b loop, which contacts one quadrant of the g subunit
(see below), before terminating with two strands of a three-
stranded b sheet, the third strand being contributed by the g sub-
unit. This method of linking the three subunits is conserved in
AMPK orthologs from humans, fission yeast, and budding yeast
(Amodeo et al., 2007; Townley and Shapiro, 2007; Xiao et al.,
2007). The N-terminal region of the b subunit (containing themyr-
istoylation site) and the 30 residues connecting the C-interacting
helix and the C-terminal domain have not been resolved in any
structure to date.
The g Subunit
It has been known for many years that the g subunit contains the
regulatory binding sites for adenine nucleotides (Cheung et al.,
2000; Scott et al., 2004). Following N-terminal regions that vary
greatly in length and sequence between different isoforms, and
a short segment providing the b strand that interacts with theC-terminal domain of the b subunit, g subunits from all species
contain four tandem cystathione b-synthase (CBS) repeats.
CBS repeats occur in a small number of other human proteins
(including cystathione b-synthase itself) (Bateman, 1997), usually
as just two repeats that form a structure known as a Bateman
domain, with a cleft between the repeats that often binds ligands
containing adenosine (Scott et al., 2004). The two Bateman do-
mains in the AMPK-g subunits assemble in a pseudosymmetri-
cal head-to-head manner, forming a flattened disk with one
CBS repeat in each quadrant. This arrangement provides four
symmetrical clefts near the center of the disk where the regula-
tory nucleotides could potentially bind; by convention (Kemp
et al., 2007), these are numbered 1–4 according to the number
of the CBS repeat providing a conserved aspartate side chain
that interacts with the ribose ring of the bound nucleotide. How-
ever, in mammalian AMPK only sites 1, 3, and 4 are utilized, with
site 2 always unoccupied (interestingly, CBS2 has an arginine in
place of the conserved aspartate). The phosphate groups of
adenine nucleotides bound at sites 1, 3, and 4 lie close together
in the center of the disk. Some amino acid side chains interact
with nucleotides at more than one site, or even with nucleotides
in different sites depending on which nucleotide is bound (Chen
et al., 2012; Xiao et al., 2007, 2011). This arrangement suggests
that there would be complex interactions between the three
sites; agreeing with this, mutations of any of the three sites re-
duces the effects of AMP on both Thr172 phosphorylation and
allosteric activation (Oakhill et al., 2010). Sites 1 and 3 are able
to bind AMP, ADP, and ATP in competition, but there is some
disagreement about site 4. It was originally suggested that site
4 only binds AMP in a nonexchangeable manner, with sites 1
and 3 being the sites where ADP or ATP exchanged with AMP
when they were soaked into crystals made using AMP (Xiao
et al., 2007; Xiao et al., 2011). However, it was subsequently re-
ported that if the core of the heterotrimeric complex was crystal-
lized in the presence of ATP rather than AMP, ATP was found at
sites 1 and 4 rather than 1 and 3 (Chen et al., 2012). Binding of
ATP rather than AMP was also observed to cause a conforma-
tional change in which the two Bateman domains (formed by
CBS1/CBS2 and CBS3/CBS4) rotated toward each other by
5, which had not been observed in the previous crystal soakingCell Metabolism 20, December 2, 2014 ª2014 Elsevier Inc. 943
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the absence of added nucleotides predominantly have AMP
rather than ATP bound at site 4, Chen et al. (2012) argued that
this site must have a higher affinity for AMP than ATP. As dis-
cussed in the next paragraph, site 3 appears to be the site where
AMP binding causes activation, but analysis of the crystals ob-
tained in the presence of ATP also suggested that binding of
ATP at site 4 would preclude binding of any other nucleotide at
site 3 (Chen et al., 2012). Thus, to obtain binding of AMP at the
critical site 3, AMP may have to be already bound at site 4, sug-
gesting a cooperative interaction between the two sites.
Intriguingly, the linker peptide between the AID and the C-ter-
minal domain of the a subunit wraps around the face of the g
subunit that contains sites 2 and 3 (Xiao et al., 2011, 2013).
One well-conserved sequence motif within this linker (a-regula-
tory subunit interacting motif-1, a-RIM1) contacts the unused
site 2, while another (a-RIM2) contacts AMP bound in site 3
(Xin et al., 2013). These authors proposed that the binding of
a-RIM1 and a-RIM2 to the g subunit when AMP is bound in
site 3 would force the AID to dissociate from the kinase domain,
thus relieving its inhibitory effects. Since this linker also forms the
hinge between the catalytic and the nucleotide-bindingmodules,
this change may also pull these modules together, reducing the
accessibility of Thr172 to protein phosphatases and protecting it
against dephosphorylation. Although this model is quite compel-
ling, more structures of mammalian heterotrimers in inactive
states will be required to confirm it. The role of nucleotide binding
at site 1, and the reason why ADP mimics only one of the three
effects of AMP, remain unclear. Also unclear is the mechanism
by which AMP binding promotes phosphorylation of Thr172 by
LKB1, although the next section describes some intriguing new
twists in this story.
LKB1 May Activate AMPK at the Lysosomal Surface in a
Reciprocal Manner with mTORC1
Using a highly purified, reconstituted cell-free system, LKB1 can
phosphorylate Thr172 and activate AMPK in a reaction stimu-
lated by AMP without requiring any additional components
(Gowans et al., 2013). However, recent remarkable results from
the group of Shengcai Lin suggest that in intact cells this interac-
tion may be facilitated by the assembly of these complexes, with
the help of various adaptor proteins, at a 2D surface, i.e., the
cytoplasmic surface of the lysosomal membrane (Zhang et al.,
2013, 2014). These studies also suggest that there are close
reciprocal interactions between the regulation of the AMPK sys-
tem, which is activated by lack of energy or nutrients, and that of
mTORC1, which is activated under the opposite circumstance,
i.e., by availability of nutrients.
Initial clues came from studies of axin, a scaffold protein orig-
inally identified as a negative regulator of Wnt signaling (Zeng
et al., 1997). Unexpectedly, knockdown of axin in mouse liver
using siRNAs caused accumulation of triglycerides that was
accompanied by reduced AMPK activation (Zhang et al.,
2013). In cell lines in which axin was knocked down, the
activation of AMPK by treatments such as glucose deprivation,
2-deoxyglucose, or AICARwas also defective. Moreover, copre-
cipitation studies suggested that axin enhanced Thr172 phos-
phorylation by assembling in a signaling complex with AMPK
and LKB1, whose formation was enhanced by prior glucose944 Cell Metabolism 20, December 2, 2014 ª2014 Elsevier Inc.deprivation of the cells. In cell lysates, coprecipitation of axin
and AMPK (but not of axin and LKB1) was promoted by AMP
and inhibited by ATP, while ADP had no effect. These results
suggested a model in which LKB1 and axin form a constitutive
complex, while AMPK is recruited to this complex when it binds
AMP, thus enhancing the phosphorylation of Thr172 and causing
AMPK activation.
Following up this study, the same group performed a two-
hybrid screen to detect axin-interacting proteins and detected
LAMTOR1 (Zhang et al., 2014), a protein that is tethered to the
lysosomal membrane by N-terminal myristoylation and palmi-
toylation and that is one of the components of the Ragulator
complex. The latter is a pentameric complex, which under
nutrient-rich conditions acts as a guanine nucleotide exchange
factor (GEF) for the small G proteins RagA or RagB (Bar-Peled
and Sabatini, 2014). In their GTP-bound state, RagA or RagB
(together with their heterodimer partners RagC or RagD) recruit
mTORC1 to the lysosomal membrane. The Ragulator also inter-
acts with the vacuolar ATPase (v-ATPase), the protein that acid-
ifies the lumen of the lysosome by pumping protons into it. This
complex is required to sense nutrients (particularly amino acids)
within the lysosomal lumen because v-ATPase inhibitors block
mTORC1 activation by nutrients, although the molecular details
of the sensing mechanism remain unclear (Bar-Peled and Saba-
tini, 2014).
Lin and colleagues (Zhang et al., 2014) also generated mice
with floxed alleles of the LAMTOR1 gene and used these to
knock out LAMTOR1 conditionally in various tissues and cells.
Remarkably, AMPK activation was defective in response to star-
vation in LAMTOR1-deficient liver, in response to exercise in
LAMTOR1-deficient muscle and in response to glucose depriva-
tion in LAMTOR1-deficient mouse embryo fibroblasts (MEFs). In
lysates derived from MEFs, anti-axin antibodies pulled down
LAMTOR1, LKB1, and AMPK, and this coprecipitation was
enhanced by prior glucose deprivation of the cells. The interac-
tion between LAMTOR1 and axin required the N-terminal region
of axin (1–400), whereas only the C-terminal region (507–731)
was required for the interaction with LKB1 and AMPK. Thus,
axin appears to be an adaptor protein that recruits LKB1 and
AMPK to the Ragulator, and hence the lysosome, under
nutrient-poor conditions. Interestingly, LAMTOR1 deficiency
did not affect activation of AMPK by the Ca2+ ionophore
A23817, and CaMKKb did not coprecipitate with axin or
LAMTOR1, suggesting that LAMTOR1 and axin are not involved
in the alternate, Ca2+-mediated pathway for AMPK activation.
By subcellular fractionation, the LAMTOR1:axin:LKB1 complex
was found in late endosomal and detergent-resistant/lipid raft
membrane fractions following glucose deprivation. Interestingly,
AMPK was detected both in these membrane fractions and
in cytosolic fractions in control incubations, and the amount
recovered in the membrane fractions did not increase upon
glucose deprivation, although its phosphorylation on Thr172
did. By fluorescence microscopy, both LKB1 and axin also colo-
calized with the lysosomal membrane marker LAMP2 following
glucose deprivation, and the translocation of LKB1 to the lyso-
somal membrane following glucose deprivation required axin,
but not AMPK.
Interestingly, AMP promoted coprecipitation of axin and
AMPK in detergent lysates of the late endosomal fraction from
Figure 4. Proposed Mechanism for Reciprocal Regulation of
mTORC1 and AMPK at the Cytoplasmic Surface of the Lysosome
The model is based on Bar-Peled and Sabatini (2014) and Zhang et al. (2014).
(1) Activation of mTORC1: nutrient availability (amino acids and/or glucose)
within the lysosome is sensed by a mechanism requiring the v-ATPase proton
pump, and this effect is transmitted to the Ragulator, which converts RagA/
BGDP to RagA/BGTP, while the folliculin:FNIP complex converts RagC/DGTP to
RagC/DGDP. The RagAGTP:RagCGDP complex binds the Raptor component of
mTORC1, whose activation also requires Rheb:GTP. Formation of the latter
complex is promoted by growth factors via phosphorylation and dissociation
from the lysosome of TSC1:TSC2, a Rheb-GAP (Menon et al., 2014).
(2) Activation of AMPK: nutrient lack causes the Ragulator to recruit the
axin:LKB1 complex, and elevated AMP also recruits AMPK to this complex.
LKB1 phosphorylates and activates AMPK, which then presumably dissoci-
ates from the complex to phosphorylate downstream targets. Two of these
targets are Raptor and the TSC1:TSC2 complex. Phosphorylation of Raptor by
AMPK, coupled with conversion of RagAGTP:RagCGDP to RagAGDP:RagCGTP,
may promote the dissociation of mTORC1 from the lysosome. Phosphoryla-
tion of the TSC1:TSC2 complex appears to increase its Rheb-GAP activity,
thus converting Rheb:GTP to the inactive Rheb:GDP form, although the exact
mechanism remains unclear.
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membrane fractions had been prepared from glucose-deprived
cells. These results suggest that the Ragulator complex some-
how senses glucose deprivation and, while this acts indepen-
dently of the canonical activation of AMPK by LKB1 in the
presence of AMP, the two regulatory systems can interact with
and reinforce each other. The Ragulator-dependent mechanism
seems to require the v-ATPase, because it was affected by
siRNA knockdown of subunits of the v-ATPase, while the
v-ATPase inhibitor concanamycin A promoted translocation of
axin and LKB1 to the lysosome, mimicking the effects of glucose
deprivation.
Taken together, these results suggest that the Ragulator com-
plex, which is known to be important for recruiting mTORC1 to
the lysosome under nutrient-rich conditions, is also involved in
the reciprocal recruitment of the axin-LKB1 complex to the lyso-
some under nutrient-poor or low-energy conditions, leading to
phosphorylation and activation of AMPK (Figure 4). Axin defi-
ciency was also found to reduce the dissociation of mTORC1
from the lysosome following a switch from nutrient-rich tonutrient-poor conditions. It was already known that activation
of AMPK causes inactivation of mTORC1 by phosphorylating
Raptor (Gwinn et al., 2008) and TSC2 (Inoki et al., 2003). Raptor
is a key component of the mTORC1 complex that interacts with
RagA/BGTP:RagC/DGDP, thus recruiting mTORC1 to the lyso-
some (Sancak et al., 2008). Phosphorylation of Raptor by
AMPK may therefore be part of the mechanism by which
mTORC1 dissociates from the lysosome under nutrient-poor
conditions.
At first sight, these findings of Lin and colleagues (Zhang et al.,
2013, 2014) seemed quite surprising, because neither axin nor
LAMTOR1 have been found to interact with LKB1 or AMPK in
protein interaction screens by other laboratories and because
their proposed new mechanism (Figure 4) also represents a
radical departure from the existing view of AMPK activation by
LKB1. However, there are other recent findings that might be
consistent with their hypothesis:
(1) Another component of mTORC1 regulation is the folliculin
complex, containing folliculin and folliculin-interacting
protein-1 or protein-2 (FNIP1/2). Loss-of-function muta-
tions in the folliculin gene (FLCN) in humans cause Birt-
Hogg-Dube´ syndrome, characterized by the formation
of frequent benign tumors of hair follicles (hence the
name), as well as increased risk of development of lung
and kidney cysts and renal cancer; folliculin is therefore
a tumor suppressor (Tee and Pause, 2013). The folliculin
complex acts as a GTPase activator protein (GAP) for
RagC/D, the heterodimer partners of RagA/B (Tsun
et al., 2013). Since recruitment of mTORC1 to the lyso-
some requires RagA/B to be in the GTP-bound form and
(unusually) RagC/D to be in the GDP-bound form, the
Ragulator and folliculin complexes are both positive reg-
ulators of mTORC1, even though one is a GEF and the
other a GAP. Interestingly, it was shown in 2006 that
AMPK interacts with FNIP1, and it was suggested that fol-
liculin was phosphorylated by AMPK, although direct
phosphorylation site(s) have not been identified (Baba
et al., 2006; Wang et al., 2010). Very recently, it has
been reported that AMPK is constitutively activated in
folliculin-deficient MEFs and that this is associated with
various metabolic changes, including increased mito-
chondrial biogenesis. Similar changes in gene expression
were observed by immunohistochemistry in renal cell car-
cinomas from Birt-Hogg-Dube´ patients (Yan et al., 2014).
Thus, folliculin appears to be a positive regulator of
mTORC1 but a negative regulator of AMPK.
(2) The major splice variant of LKB1 expressed in most cell
types (Towler et al., 2008) contains a C-terminal CKQQ
sequence where the cysteine residue is modified by far-
nesylation. Recently, a knockin mouse with a C/Smuta-
tion that prevents farnesylation was generated (Houde
et al., 2014). The lack of farnesylation did not affect the
intrinsic activity of LKB1 measured using a peptide sub-
strate, but the activation of AMPK and the phosphoryla-
tion of downstream targets in isolated hepatocytes in
response to AICAR, and during in situ contraction or
AICAR treatment in skeletal muscle in vivo, was impaired.
There was also a significantly smaller proportion of theCell Metabolism 20, December 2, 2014 ª2014 Elsevier Inc. 945
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brane fractions in mouse liver or MEFs. These authors
proposed that the farnesylation of LKB1 and the b subunit
myristoylation of AMPK might cause them to associate
together at a membrane surface, thus facilitating their
interaction (Houde et al., 2014).
(3) On glucose deprivation of COS7 cells expressing wild-
type GFP-tagged AMPK, GFP fluorescence changed
from a diffuse cytoplasmic signal that was lost when the
plasma membrane was permeabilized with digitonin to a
speckled perinuclear pattern that was digitonin resistant.
By contrast, in cells expressing a nonmyristoylatable
G2A mutant the cytoplasmic fluorescence was unaf-
fected by glucose deprivation, and the speckled perinu-
clear pattern was not seen (Oakhill et al., 2010). Based
on the recent findings of Lin and colleagues (Zhang
et al., 2013, 2014), it is tempting to speculate that the
speckled perinuclear location to which AMPK migrates
on glucose deprivation is the lysosome and that the farne-
sylation of LKB1 might also help to colocalize it on the
lysosomal surface with axin.
Taking all of these observations together, the lysosomal sur-
face may represent a key locus where nutrients are sensed in a
reciprocal manner by both the mTORC1 and the AMPK signaling
pathways. mTORC1 is activated by the availability of nutrients
and promotes cell growth and proliferation and the associated
metabolic changes (e.g., expression of HIF-1a, leading to
increased glucose uptake and aerobic glycolysis; Shackelford
et al., 2009), whereas AMPK is activated by lack of nutrients,
inhibits cell growth and proliferation, and promotes the more
energy-efficient oxidative metabolism exhibited by most quies-
cent cells. By phosphorylating Raptor, AMPK may also be
involved in promoting dissociation of mTORC1 from the lyso-
somal membrane under nutrient-poor conditions.Why Might AMPK and mTORC1 Sense Nutrients at the
Lysosome?
One canmake several evolutionary arguments as to why nutrient
sensing might have developed at the lysosome. Many heterotro-
phic protists, such as flagellates, ciliates, and amoebas, feed pri-
marily by phagocytosis, which delivers macromolecules directly
to lysosomes or vacuoles without passage through the cyto-
plasm. Lysosomes or vacuoles in unicellular organisms can
therefore be regarded as the equivalent of the gut in a multicel-
lular organism. All eukaryotic cells also carry out autophagy,
the process by which organelles and macromolecular com-
plexes, such as protein aggregates or glycogen particles, are
engulfed by autophagosomes and delivered to lysosomes for
digestion. Indeed, AMPK plays a fundamental role in switching
on autophagy during starvation by phosphorylating ULK1, the
protein kinase that initiates the process (Egan et al., 2011). Plant
and fungal cells contain vacuoles, which are essentially very
large lysosomes that can be used for long-term storage of nutri-
ents and other purposes. Interestingly, in the budding yeast
Saccharomyces cerevisiae there appear to be two pools of
glycogen, a cytoplasmic pool that can be rapidly mobilized by
phosphorylase (encoded byGPH1) during early stationary phase
and a vacuolar pool mobilized by a-glucosidase (encoded by946 Cell Metabolism 20, December 2, 2014 ª2014 Elsevier Inc.SGA1) during late stationary phase (Wilson et al., 2010). These
two pools can be distinguished by mutations in GPH1 or SGA1
(which both cause increased glycogen accumulation, but at
different stages during stationary phase), and because the vacu-
olar pool does not form in strains with mutations in genes
required for autophagy. Intriguingly, deletion of any one of 12
genes required for the structure or assembly of the v-ATPase
also leads to glycogen accumulation, which may occur because
acidification of the vacuole fails to occur, and this is necessary
for the activity of the vacuolar a-glucosidase encoded by
SGA1 (Wilson et al., 2002). Glycogen breakdown can also occur
in lysosomes in mammals, particularly during the neonatal
period. Thus, human cells also express a lysosomal a-glucosi-
dase, whose genetic loss is fatal during the first year of life.
Interestingly, following the birth of rats, numerous glycogen-con-
taining autophagosomes rapidly appear in the liver and muscle
and then disappear within a few hours (Schiaffino et al., 2008).
In addition, mice with knockouts in the autophagy genes Atg5
and Atg7 are born at the expected frequency but die within
1 day of birth (Komatsu et al., 2005; Kuma et al., 2004). Mice
with a knockin mutation in RagA that inhibits its GTPase activity
and locks it in its GTP-bound state, thus activating mTORC1
irrespective of nutrient supply, also die within a few hours of
birth. This appears to occur because they are unable to respond
to the profound hypoglycemia that follows the loss of nutrient
supply from the placenta by switching off mTORC1 and inducing
autophagy (Efeyan et al., 2013). It appears that lysosomal
glycogen breakdown may be particularly important in newborn
mammals, which must rapidly switch from the placenta to the
gut for their source of nutrients. All of these observations suggest
that the lysosome or vacuole can be an important site where
sensing of glucose has to occur.
Crosstalk between AMPK and Other Pathways
Phosphorylation of the ST Loop of AMPK by Akt, PKA,
and GSK3
When the sequences of AMPK-a subunits from different species
are aligned, a1 and a2 sequences from vertebrates and Caeno-
rhabditis elegans can be seen to contain a serine/threonine-rich
insert of about 55 amino acids, just preceding the final a-helix
with its nuclear export sequence. This ST loop is absent or trun-
cated in sequences from other invertebrates such as Drosophila
melanogaster or Saccharomyces cerevisiae (Figure 5) and is not
resolved in any existing crystal structures, suggesting that it is
mobile within the crystals. I will now discuss the evidence that
phosphorylation at one or more sites within this loop downregu-
lates AMPK signaling.
The phosphatidylinositol 3-kinase (PI3K) / Akt pathway is
activated by binding of insulin or insulin-growth factor-1 (IGF1)
to their cognate receptors, with PI3K generating the Akt-acti-
vating second messenger, PI-3,4,5-trisphosphate (PIP3). These
hormones are signals emanating from elsewhere in the body
indicating either that nutrients are available (insulin) or that con-
ditions are suitable for cell growth (IGF1). In general, insulin pro-
motes the uptake of nutrients (glucose, fatty acids, and amino
acids) and their anabolic conversion to macromolecular storage
forms, i.e., glycogen, triglycerides, and proteins. Although AMPK
can also stimulate uptake of glucose and fatty acids, it does
so for a different purpose, i.e., their catabolic breakdown to
Figure 5. Alignment of Sequences at the C-Terminal End of the a Subunits, Showing the Location of the ST Loop
Sequences were aligned using CLCMainWorkbench 6 using a ‘‘gap open cost’’ of 10 and a ‘‘gap extension cost’’ of 1. Serine and threonine residueswithin the ST
loop are highlighted in bold type, with residues where there is evidence for phosphorylation shown with arrows (human residue numbering). Also shown are the
nuclear export sequences at the extreme C termini, with critical hydrophobic residues highlighted in bold.
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fore essentially antagonistic, and it is perhaps not surprising
that there should be mechanisms by which Akt downregulates
AMPK. In 2006, it was reported that Akt phosphorylated
Ser485 of rat a1, which lies within the ST loop. Evidencewas pre-
sented that this phosphorylation inhibited the phosphorylation
of Thr172 by LKB1, and consistent with this, prior treatment of
perfused rat hearts with insulin caused phosphorylation of
Ser485, and this was associated with reduced Thr172 phosphor-
ylation during subsequent ischemia (Horman et al., 2006). Our
group has recently confirmed and extended these observations
and provided evidence for a molecular mechanism for the effect
(Hawley et al., 2014). We were able to confirm that Ser487 on hu-
man a1 (corresponding to Ser485 in rat a1; to avoid confusion I
will use human residue numbering in the following text and in
Figure 5) was a good substrate for Akt. However, the equivalent
residue on human a2, Ser491, was an extremely poor substrate
for Akt, although subject to rapid autophosphorylation. Consis-
tent with this, Ser487 on a1 became phosphorylated when cells
were incubated with IGF1 to activate Akt, but not when incu-
bated with berberine to activate AMPK, whereas the converse
was true for Ser491 on a2. Pretreatment of cells expressing
wild-type a1 with IGF1 greatly reduced subsequent Thr172
phosphorylation in response to A769662, but this effect was
completely abolished in cells expressing an S487A mutant. To
place these observations in the context of cancer, in three
different tumor cell lines in which Akt was hyperactivated due
to loss of PTEN (the phosphatase that breaks down PIP3), there
was only amodest Thr172 phosphorylation and AMPK activation
in response to A769662, but full effects could be restored either
by adding a selective Akt inhibitor or by re-expressing PTEN.
These results show that a previously unrecognized effect of
Akt hyperactivation in tumor cells (which can also occur due to
mutations in PI3K or upstream receptors) is that AMPK activation
is downregulated, removing the restraining influences that
AMPK might otherwise have on cell growth and proliferation.
We also established the likely mechanism for these effects of
Ser487 phosphorylation (Hawley et al., 2014). Although the ST
loop is not resolved in the crystal structures, the residues at
the ends of the missing loop lie quite close to Thr172. This sug-
gested that when the ST loop was phosphorylated it could
interact with the kinase domain, blocking access of upstream ki-
nases to Thr172. We noticed a series of basic residues within theC-helix of the N-lobe of the kinase domain (Arg64, Lys71, and
Arg74) that are conserved in all vertebrate AMPK-a subunits,
but not in most other kinases. Our hypothesis is that phosphor-
ylated side chains on the ST loop interact with these basic resi-
dues, anchoring the loop to the N-lobe of the kinase domain and
thus blocking access to Thr172. We tested this using two
approaches: (i) a synthetic peptide corresponding to the ST
loop inhibited Thr172 phosphorylation and activation of a
human a1b2g1 complex, but only when phosphorylated on the
residue equivalent to Ser487; (ii) the inhibitory effect of Ser487
phosphorylation was completely abolished by a triple mutation
of the C-helix (R64A/K71A/R74A), although kinase activity and
Ser487 phosphorylation were unaffected. Prior Ser487 phos-
phorylation also inhibited Thr172 phosphorylation by CaMKKb
as well as LKB1, supporting a mechanism involving physical
exclusion of the upstream kinases from Thr172. How Ser487
phosphorylation might affect dephosphorylation of Thr172 has
not yet been addressed.
Other protein kinases may also phosphorylate the ST loop.
Hurley et al. (2006) reported that Ser487/491 on AMPK-a1 or
AMPK-a2 (the isoform was not specified) was phosphorylated
in response to the cyclic AMP-elevating agents in the pancreatic
b cell line, INS-1. A recombinant AMPK-a1 peptide could also be
phosphorylated at Ser487 by cyclic AMP-dependent protein ki-
nase (PKA) in cell-free assays. Complicating this story, however,
CaMKKb appeared to be inactivated by cyclic AMP-elevating
agents in INS-1 cells, and their effects on AMPK were abolished
in CaMKKb null MEFs, suggesting that they were mediated by
modulation of CaMKKb rather than AMPK (Hurley et al., 2006).
To add further complications, using a bacterially expressed
AMPK complex (a1b1g1), PKA was found to phosphorylate not
only Ser487, but also Ser499 (also within the ST loop) as well
as Ser175 (within the activation loop and adjacent to Thr174,
the residue equivalent to Thr172 in human a1). Variousmutations
at these sites were generated, and their analysis suggested that
it was phosphorylation at Ser175, rather than Ser487 or Ser499,
that blocked subsequent Thr174 phosphorylation and AMPK
activation. These authors also provided evidence that this mech-
anism of downregulation of AMPK by PKA limited the ability of
AMPK to inhibit lipolysis in white adipocytes (Djouder et al.,
2010). A puzzling feature of this paper is that the authors did
not observe any effect on subsequent Thr172 phosphorylation
when Ser487 was phosphorylated by PKA, even though thisCell Metabolism 20, December 2, 2014 ª2014 Elsevier Inc. 947
Figure 6. Proposed Reciprocal Feedback Loops Operating between
the Raf-MEK-ERK-RSK and LKB1-AMPK Signaling Pathways
In the inactive state of B-Raf, phosphorylation of Ser365 and Ser729 (the
latter by AMPK; Shen et al., 2013) causes binding of 14-3-3 proteins that
prevent association of B-Raf with the plasma membrane and with the Raf-
like scaffold proteins KSR1 or KSR2. When Ras is activated, it binds to the
Ras-binding region of the B-Raf CR1 domain, relieving the inhibitory effect
of the latter, and if 14-3-3 proteins are not bound to B-Raf, KSR1 or KSR2
then forms a complex with B-Raf and MEK, causing phosphorylation and
activation of the latter by B-Raf. This in turn triggers a cascade of phosphor-
ylation and activation of the downstream kinases ERK and RSK. The latter
phosphorylate LKB1 at Ser325 and Ser428, respectively, reducing its ability
to activate AMPK via phosphorylation of Thr172 (Zheng et al., 2009). For
more details of the conserved domains on B-Raf, KSR1, and KSR2, see Udell
et al. (2011).
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was phosphorylated by Akt.
In addition to Ser487 and Ser499, the ST loop may be regu-
lated by phosphorylation at other sites. Suzuki et al. (2013) re-
ported that the protein kinase GSK3b phosphorylated Thr481
and Ser477 (within the ST loop just N-terminal to Ser487), that
this was primed by phosphorylation of Ser487, and that this
further inhibited AMPK by promoting Thr172 dephosphoryla-
tion. While this is an interesting proposal, the physiological
rationale underlying inhibition of AMPK by GSK3 is difficult to
grasp because both GSK3 isoforms (a and b) are inactivated
by phosphorylation by Akt and because GSK3 generally acts,
like AMPK and in contrast to Akt, to inhibit rather than promote
anabolic pathways. For example, GSK3 and AMPK both inacti-
vate glycogen synthase and hence glycogen synthesis (Carling
and Hardie, 1989; Jørgensen et al., 2004; McManus et al.,
2005).
As discussed earlier, Ser487 on a1 is a good target for Akt,
whereas the equivalent site on a2, Ser491, is a very poor sub-
strate for Akt and appears to be modified by autophosphoryla-
tion instead (Hawley et al., 2014). It will therefore be important
to examine the role of ST loop phosphorylation using the individ-
ual a subunit isoforms of AMPK rather than simply assuming that
results obtained with one isoform will be applicable to the other.
For example, it has been suggested that p70 S6 kinase directly
phosphorylates Ser491 in a recombinant a2b1g1 complex and948 Cell Metabolism 20, December 2, 2014 ª2014 Elsevier Inc.that this explains how leptin inhibits AMPK in the hypothalamus
(Dagon et al., 2012). While this is an attractive hypothesis, the
evidence that S6 kinase directly phosphorylates Ser491 was
based mainly on the acquisition of signal using an anti-pS491
phosphospecific antibody, which gives no information about
the real extent of phosphorylation. Given our own findings (Haw-
ley et al., 2014), it is also puzzling as to why these authors did not
observe autophosphorylation when the a2b1g1 complex was
incubated without S6 kinase. In addition, there is no direct evi-
dence that phosphorylation of Ser491 on a2 downregulates
Thr172 phosphorylation, which has currently only been demon-
strated for Ser487 on a1.
Crosstalk between theAMPKand theRas-Raf-MEK-ERK
Pathways
A-Raf, B-Raf, and c-Raf are paralogous protein kinases involved
in the Ras-Raf-MEK-ERK pathway by which the effects of many
growth factor receptors on cell growth and proliferation are
transduced. The role of B-Raf in cancer was highlighted by find-
ings that a V600E mutation in its activation loop, which causes
constitutive activation, is present in around 50% of all cases of
malignant melanomas and in smaller proportions of other can-
cers (Davies et al., 2002). It was shown many years ago that
AMPK phosphorylates a site near the C terminus of c-Raf,
Ser621, in cell-free assays (Sprenkle et al., 1997); recently, this
has been reinvestigated. Despite the fact that the sequence
around Ser621 is a good fit for the consensus recognition motif
for AMPK (Gwinn et al., 2008; Scott et al., 2002), treatment of
MEFs with the AMPK activator A769662 did not appear to cause
increased phosphorylation of c-Raf at Ser621. However, it did
cause increased phosphorylation of B-Raf at the equivalent
site, Ser729, as well as attenuation of ERK activation, and both
effects were lost in AMPK knockout MEFs (Shen et al., 2013).
When B-Raf was re-expressed in B-Raf-deficient MEFs, the abil-
ity of AMPK activators to inhibit ERK activation was regained
using wild-type B-Raf, but not an S729A mutant; a keratinocyte
cell line expressing the S729A mutant B-Raf also proliferated
more rapidly than cells expressing the wild-type. Phosphoryla-
tion of Ser729 on B-Raf does not directly inhibit its kinase
activity, but instead promotes 14-3-3 binding and thus prevents
association of B-Raf with KSR1, a scaffold protein with a kinase-
like domain related to the Raf kinases, on which the latter nor-
mally assemble with their downstream kinases MEK and ERK
to trigger downstream signaling (Shen et al., 2013) (Figure 6).
Inhibitors of oncogenic B-RafV600E, such as vemurafenib and
dabrafenib, are initially very effective in treating melanomas
carrying the mutation, but unfortunately resistance to these
drugs develops rapidly and disease returns. However, following
their findings suggesting that AMPK downregulated B-Raf
signaling, the same group showed that treatment of melanoma
cells with a combination of PLX4720 (a relative of vemurafenib)
and phenformin (a more cell-permeable relative of metformin)
enhanced apoptosis and reduced cell viability in a synergistic
manner, delayed the emergence of PLX4720 resistance in a
cell culture model, and induced tumor regression in xenograft
and genetically engineered (B-RafV600E/PTEN/) mousemodels
of melanoma (Yuan et al., 2013). These results suggest that the
AMPK activators metformin or phenformin might be useful
adjuncts for therapy of human melanoma patients with B-Raf
inhibitors.
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to be downregulated in cells expressing the B-Raf V600E muta-
tion; this was associated with phosphorylation by ERK and RSK
of two sites on LKB1 that were proposed to negatively regulate
phosphorylation of AMPK (Zheng et al., 2009). Thus, there
appear to be two opposing negative feedback loops operating
between B-Raf and AMPK (Figure 6).
Although the molecular details are less clear, there are other
possible connections between the Ras-Raf-MEK-ERK and
AMPK pathways. KSR2 is a paralog of KSR1; protein interaction
screens identified several AMPK subunits (a1, a2, b1, g1) as
binding partners that had a preference for KSR2 over KSR1
(Costanzo-Garvey et al., 2009). Although only KSR1 is detect-
able in MEFs, neither ksr1/ nor ksr2/ MEFs were able to
oxidize exogenous fatty acids, but this was restored by overex-
pression of either KSR1 or KSR2; this required the region of
these proteins (between domains CA2 and CA3) that interact
with AMPK. Interestingly, KSR2 knockout mice become obese,
glucose intolerant, and insulin resistant as adults, which ap-
peared to be due to reduced energy expenditure rather than
increased food intake. The phosphorylation of AMPK in
response to AICAR in explants of white adipose tissue from
wild-typemicewas lost in the KSR2/mice, and genes involved
in oxidative metabolism were also downregulated in white adi-
pose tissue. Interestingly, this function of KSR2 appears to
translate into humans (Pearce et al., 2013) because in a screen
of around 2,000 obese humans, a significantly higher proportion
had heterozygous mutations in the KSR2 gene compared with
lean controls. Heterozygous carriers of human KSR2 mutations
had lower basal metabolic rates and higher respiratory quo-
tients, the latter indicating a relative deficit in fat oxidation.
Finally, fatty acid oxidation was enhanced in myotubes that
had been differentiated from C2C12 myoblasts transfected
with DNA encoding wild-type KSR2, but this was partially or
completely abolished using most of the human KSR2 mutants,
although the defect could be restored in every case by treating
the cells with metformin (Pearce et al., 2013). Thus, KSR2
appears to be required for the ability of AMPK to promote fatty
acid oxidation. However, the molecular mechanisms underlying
this remain obscure, particularly because by western blotting
KSR2 is only detectable in mouse brain; very low levels of
mRNA are detectable in liver and muscle, and essentially none
in adipose tissue (Costanzo-Garvey et al., 2009). It is therefore
not clear that the effect of KSR2 loss on AMPK activation in vivo
is a cell-autonomous process.
Conclusions and Future Challenges
The canonical regulation of AMPK by adenine nucleotides
and by phosphorylation of Thr172 is now well understood,
and the recent crystal structure of a complete human AMPK
heterotrimer (Xiao et al., 2013) has provided many insights
into how this regulation operates at the molecular level. How-
ever, elucidation of some details of the activation mechanism,
such as the exact roles of the three individual adenine nucleo-
tide-binding sites, how they distinguish between AMP, ADP,
and ATP, and the mechanism by which combinations of
allosteric activators (AMP and A769662) can mimic the effects
of phosphorylation, remain for the future. Another remaining
challenge is the identification of natural ligands (other thansalicylate) that bind at the same site as the synthetic activator
A769662.
Particularly exciting developments in the past year have con-
cerned the mechanisms by which the AMPK pathway talks to
other signaling pathways. It appears that that LKB1 and AMPK
do not simply wait to collide within the three dimensions of the
cytoplasm but are brought together on the 2D surface of the
lysosome by the adaptor proteins axin and LAMTOR1, where
the reciprocal regulation of mTORC1 and AMPK may be inti-
mately linked (Zhang et al., 2014). Although both are absent in
the obligate parasite E. cuniculi (Miranda-Saavedra et al.,
2007), genes encoding the mTORC1 and AMPK pathways are
present in the genome of Giardia lamblia, which has the smallest
kinome of any free-living eukaryote and appears to have
branched very early from the main eukaryotic lineage (Manning
et al., 2011). The mTORC1 and AMPK pathways were therefore
probably among the first signaling pathways to have developed
during evolution of eukaryotes, where their functions may have
been to sense to the availability, or lack of availability, of nutrients
that were delivered to the lysosome or vacuole by phagocytosis
or autophagy and to regulate cell growth and metabolism
accordingly. However, the complex crosstalk between AMPK
and other signaling pathways that arose later during the develop-
ment of multicellular animals, such as the insulin/IGF1 and Ras-
Raf-MEK-ERK pathways, is also now being unraveled.
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